Sage Journals: Discover world-class research

Abstract

Objectives:

Extracorporeal Life Support (ECLS) risks thrombotic and hemorrhagic complications. Optimal anti-coagulation monitoring is controversial. We compared coagulation tests evaluating the heparin effect in pediatric ECLS.

Methods:

A retrospective study of children (<18yrs) undergoing ECLS over 12 months in a tertiary pediatric intensive care unit (PICU). Variables included anti-Factor Xa activity (anti-Xa), activated partial thromboplastin time (aPTT), activated clotting time (ACT) and thromboelastogram (TEG^®6s) parameters: ratio and delta reaction (R) times (the ratio and difference, respectively, between R times in kaolin assays with and without heparinase). Test results were correlated with unfractionated heparin infusion rate (IU/kg/hr) at the time of sampling. Mean test results of each ECLS run were evaluated according to the presence/absence of complications.

Results:

Thirty-two ECLS runs (31 patients) generated 695 data-points for correlation. PICU mortality was 22% and the thrombotic complication rate was 66%. The proportion of variation in coagulation test results explained by heparin dose was 13.3% for anti-Xa, 11.9% for ratio R time, and 9.9% for delta R time, compared with <1% for ACT and aPTT. Incorporating individual variation, age and antithrombin activity in a model with heparin dose explained less than 50% of the variation in test results. Correlation varied according to age, day of ECLS run and between individuals, with parallel dose-response lines noted between patients. Significantly lower mean anti-Xa was observed in PICU non-survivors and runs with thrombosis.

Conclusion:

Lower anti-Xa was observed in ECLS runs with complications. Although absolute results from anti-Xa and TEG6^®s showed the best correlation with heparin dose, a large proportion of variation in results was unexplained by heparin, while dose response was similar between individuals. Population pharmacokinetic/pharmacodynamic modelling is required, as well as prospective trials to delineate the superior means of adjusting heparin therapy to prevent adverse clinical outcomes.

Keywords

blood coagulation tests intensive care units pediatric heparin thromboelastography child extracorporeal membrane oxygenation

Get full access to this article

View all access options for this article.

References

Nguyen

Musick

Teruya

Anticoagulation monitoring during extracorporeal membrane oxygenation: is anti-factor Xa assay (heparin level) a better test?*. Pediatr Crit Care Med 2014; 15: 178–179.

Stocker

Horton

SB.

Anticoagulation strategies and difficulties in neonatal and paediatric extracorporeal membrane oxygenation (ECMO). Perfusion 2016; 31: 95–102.

Bembea

Annich

Rycus

Oldenburg

Berkowitz

Pronovost

Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med 2013; 14: e77–84.

Bembea

Schwartz

Shah

et al . Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO J 2013; 59: 63–68.

Annich

Adachi

Anticoagulation for pediatric mechanical circulatory support. Pediatr Crit Care Med 2013; 14: S37–42.

Annich

G MM

Lequier

Blood biomaterial surface interaction during ECLS. In: Annich

GLW

MacLaren

Wilson

Bartlett

, editor. ECMO: Extracorporeal Cardiopulmonary Support in Critical Care. Ann Arbor: ELSO; 2012, pp. 75–86.

Miller

Bailey

Mancuso

et al . Functional maturity of the coagulation system in children: an evaluation using thrombelastography. Anesth Analg 1997; 84: 745–748.

Newall

Ignjatovic

Johnston

et al . Clinical use of unfractionated heparin therapy in children: time for change? Br J Haematol 2010; 150: 674–678.

Liveris

Bello

Friedmann

et al . Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*. Pediatr Crit Care Med 2014; 15: e72–79.

10.

Oliver

WC.

Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009; 13: 154–175.

11.

Baird

Zurakowski

Robinson

et al . Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. Ann Thorac Surg 2007; 83: 912–919; discussion 919–920.

12.

Hirsh

Raschke

Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S.

13.

Khaja

Bilen

Lukner

Edwards

Teruya

Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol 2010; 134: 950–954.

14.

Monagle

Anticoagulation in the young. Heart 2004; 90: 808–812.

15.

Nankervis

Preston

Dysart

et al . Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J 2007; 53: 111–114.

16.

Maul

Wolff

Kuch

Rosendorff

Morell

Wearden

PD.

Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med 2012; 13: e363–371.

17.

Irby

Swearingen

Byrnes

Bryant

Prodhan

Fiser

Unfractionated heparin activity measured by anti-factor Xa levels is associated with the need for extracorporeal membrane oxygenation circuit/membrane oxygenator change: a retrospective pediatric study. Pediatr Crit Care Med 2014; 15: e175–182.

18.

Hoffman

Monroe

3rd . A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958–965.

19.

Gurbel

Bliden

Tantry

et al . First report of the point-of-care TEG: a technical validation study of the TEG-6S system. Platelets 2016; 27: 642–649.

20.

Haemonetics^®. Introducing TEG^®6s. Chicago, USA: Haemonetics Corporation; 2015. pp. 4–11.

21.

Alexander

Butt

Best

Donath

Monagle

Shekerdemian

LS.

Correlation of thromboelastography with standard tests of anticoagulation in paediatric patients receiving extracorporeal life support. Thromb Res 2010; 125: 387–392.

22.

Straney

Clements

Parslow

et al . Paediatric index of mortality 3: an updated model for predicting mortality in pediatric intensive care*. Pediatr Crit Care Med 2013; 14: 673–681.

23.

Dalton

Garcia-Filion

Holubkov

et al . Association of bleeding and thrombosis with outcome in extracorporeal life support. Pediatr Crit Care Med 2015; 16: 167–174.

24.

Bain

I. Laffan, M. Lewis, S. et al.

Dacie & Lewis Practical Haematology, Chapters 19 and 20. Philadelphia: Churchill Livingstone Elsevier Ltd; 2012

25.

Tientadakul

Kongkan

Chinswangwatanakul

Use of an automated coagulation analyzer to perform heparin neutralization with polybrene in blood samples for routine coagulation testing: practical, rapid, and inexpensive. Arch Pathol Lab Med 2013; 137: 1641–1647.

26.

Galeone

Rotunno

Guida

et al . Monitoring incomplete heparin reversal and heparin rebound after cardiac surgery. J Cardiothorac Vasc Anesth 2013; 27: 853–858.

27.

Ranucci

Baryshnikova

Isgro

et al . Heparin-like effect in postcardiotomy extracorporeal membrane oxygenation patients. Crit Care 2014; 18: 504.

28.

Nicolau-Raducu

Occhipinti

Marshall

et al . Thromboprophylaxis with heparin during orthotopic liver transplantation: comparison of Hepcon HMS Plus and Anti-Xa assays for low-range heparin. J Cardiothorac Vasc Anesth 2017; 31: 575–581.

29.

Arnold

Jackson

Wallis

Smith

Bolton

Haynes

Coagulation factor activity during neonatal extra-corporeal membrane oxygenation. Intensive Care Med 2001; 27: 1395–1400.

30.

Andrew

Marzinotto

Massicotte

et al . Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994; 35: 78–83.

31.

Kemme

Burggraaf

Schoemaker

Kluft

Cohen

AF.

Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. Br J Clin Pharmacol 2002; 54: 627–634.

32.

Sheffield

Blajchman

MA.

Defining the heparin-binding domain of antithrombin. Blood Coagul Fibrinolysis 1994; 5: 83–95.

33.

Gruenwald

Manlhiot

Abadilla

et al . Heparin brand is associated with postsurgical outcomes in children undergoing cardiac surgery. Ann Thorac Surg 2012; 93: 878–882.

34.

Green

Timmons

Fackler

Moler

Thompson

Sweeney

MF.

The impact of extracorporeal membrane oxygenation on survival in pediatric patients with acute respiratory failure. Pediatric Critical Care Study Group. Crit Care Med 1996; 24: 323–329.

35.

Chan

Black

Ing

Brandao

Williams

Utility of aPTT in monitoring unfractionated heparin in children. Thromb Res 2008; 122: 135–136.

36.

Denson

Bonnar

The measurement of heparin. A method based on the potentiation of anti-factor Xa. Thromb Diath Haemorrh 1973; 30: 471–479.

37.

Junker

Kase

Schulte

Baumer

Langer

Nowak-Gottl

Interferences in coagulation tests—evaluation of the 570-nm method on the Dade Behring BCS analyser. Clin Chem Lab Med 2005; 43: 244–252.

38.

Moganasundram

Hunt

Sykes

et al . The relationship among thromboelastography, hemostatic variables, and bleeding after cardiopulmonary bypass surgery in children. Anesth Analg 2010; 110: 995–1002.

39.

Pekelharing

Furck

Banya

Macrae

Davidson

SJ.

Comparison between thromboelastography and conventional coagulation tests after cardiopulmonary bypass surgery in the paediatric intensive care unit. Int J Lab Hematol 2014; 36: 465–471.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.28 MB

Coagulation monitoring correlation with heparin dose in pediatric extracorporeal life support

Abstract

Objectives:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material